Abstract
Autophagy is activated in response to a variety of stress conditions including anti-cancer therapies, and tumors cells often depend on autophagy for survival. In this study, we have evaluated inhibition of autophagy as therapeutic strategy in acute lymphoblastic leukemia (ALL) in children, both as a single treatment and in combination with glucocorticoid (GC) Dexamethasone (Dexa). Analysis of proteomics and RNA-seq of ALL cell lines and primary samples identified an upregulation of Vps34 and ATG14 proteins and autophagy and lysosomal pathway enrichment in a genetic subgroup with a recurrent t(12;21) translocation. Cells from this sugbroup were also significantly more sensitive to the selective autophagy or lysosomal inhibitors than cells with other genetic rearrangements. Further, combination of Dexa with either lysosomal or autophagy inhibitors was either synergistic or additive in killing leukemic cells across various genetic and lineage backgrounds, for both cell lines and primary samples, as assessed using viability assays and SynergyFinder as well as apoptotic caspase 3/7-based live-cell assays. Our data demonstrate that targeting autophagy represents a promising strategy for the treatment of pediatric ALL, both as a selective modality for the t(12;21) pre-B-ALL subgroup, and in combination treatments to sensitize to GC-induced cytotoxicity.
Subject terms: Cell biology, Drug discovery, Cancer, Cancer therapy, Haematological cancer, Paediatric cancer
Introduction
Autophagy is a conserved cellular program utilized by the eukaryotic cell to recycle its own constituents, such as damaged organelles or protein aggregates. It is characterized by the formation of autophagosomes, double membrane-surrounded vesicles that engulf protein aggregates or organelles, like mitochondria, and then fuse with lysosomes where the cargo is degraded1. The lipid kinase Vps34, also known as class III phosphatidylinositol-3 kinase, plays a central role in autophagy initiation, which is manifested by a formation of a protein complex between Vps34, Vps15, Beclin-1 and ATG14, called PI3-kinase Complex I, leading to its tethering to a membrane and initiation of formation of an autophagosome. Vps34 is also involved in endosomal trafficking, and to perform this function forms another type of complex, referred to as Complex II2,3. Autophagy is activated as a survival strategy in response to stressors such as starvation, hypoxia, and cytotoxic anti-cancer therapy, as we as others have established4,5. Thus, the discovery that autophagy may limit the cytotoxic effects of anti-cancer drugs has led to the initiation of clinical trials using the lysosomal inhibitor chloroquine (CQ) or hydroxychloroquine (HCQ) in combination therapies1. We and others have also shown that combination of anti-cancer drugs with more selective autophagy inhibitors, such as Vps34 inhibitors, had synergistic or additive effects in breast cancer models4. Several companies have developed selective Vps34 inhibitors: SB02024 by Sprint Bioscience4, SAR405 by Sanofi6 and a more potent PIK-III by Novartis7. Another inhibitor targeting selectively PI3-kinase Complex I has been reported to disrupt complex formation between ATG14 and Beclin-18.
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children9. There are more than ten different genetic subgroups in pediatric ALL characterized by recurring genetic abnormalities such as chromosomal translocations, gene amplifications and mutations10. The stratification of patients for treatment is based on genetic aberrations, age, and immune cell type, and treatment regimens typically involve similar drugs adjusted to risk stratification by changes in frequency and doseage. These drugs include high dose of the metabolic hormones glucocorticoids (GC), such as Dexamethasone (Dexa), in combination with L-asparaginase and multi-agent chemotherapy. Despite the high current survival rate of 90%, some 20% of pediatric ALL patients relapse owing to the development of resistance to therapy and many more are at risk for long-term toxicities9. Each of the genetic sub-groups with subtle genetic abnormalities may, however, present with unique opportunities for targeted therapy, and thus may benefit from a personalized treatment approach, such as recurring t(9;22) translocation in leukemic cells, where targeted therapy against BCR-ABL is applied. Interestingly, a recent study revealed that in a genetic sub-group of ALL with a recurrent t(12;21) resulting in ETV6-RUNX1 fusion protein (also known as TEL-AML1), Vps34 is up-regulated11. This study showed that such cells are particularly sensitive to the lysosomal inhibitor CQ.
GCs are essential drugs in the treatment of ALL, and general treatment failure has been related specifically to GC-resistance12. We have previously revealed a profound induction of autophagy in GC-treated cells and suggested its involvement in GC-induced cell death13. In a more recent study, applying proteomics and metabolomics, we found that lysosomal enzymes were also upregulated by Dexa14. The present study was designed to determine whether autophagy inhibition can be beneficial for the treatment of pediatric ALL. For this, we assessed expression levels of Vps34 and sensitivity to autophagy inhibition in leukemic cells with different genetic backgrounds and asked whether inhibition of autophagy will potentiate or protect cells from GC-induced toxicity. We used pharmacological inhibition of either the initial stage of autophagy or of the lysosomal stage alone or in combination with Dexa treatment, and both in the cell lines and primary ALL cells.
Results
Autophagy is elevated in leukemic cells with the t(12:21) translocation
Using our recently published and publicly available data15, we assessed the activity of autophagy and lysosomal pathways in a panel of 41 Pre-B-ALL cell lines, based on transcriptomic and proteomic profiles. Using Principal component analysis (PCA) of RNAseq data, the cell lines were clustered according to their cytogenic background (Fig. 1a). Gene enrichment analysis (GSEA) showed that cell lines with ETV6-RUNX1 t(12:21) had activated autophagy pathway as compared to all other cell lines (Fig. 1b). Furthermore, analysis using DESeq showed that a large number of autophagy-related and lysosomal degradation-related genes were significantly more expressed in cell lines with ETV6-RUNX1 t(12;21) translocation than in other pre-B-ALL cell lines (Supplementary Fig. 1a, b). At the protein level, Vps34 and ATG14, both crucial for autophagy initiation, were expressed at significantly higher levels in cell lines bearing t(12;21) (Fig. 1c). Further, in a cohort of 419 pediatric ALL patients PIK3C3 and ATG14 mRNA were expressed at higher levels in the ETV6-RUNX1 t(12;21) subgroup (Fig. 1d). Using the online platform tool at https://www.proteomics.se/deepmeltome/.16 for analysis of proteoforms, we detected two main proteoforms of Vps34 at 41°C in most cell lines (Supplementary Fig. 1c, d). One of the Vps34 proteoforms (membership 1 in red color) was clearly more abundant in the ETV6-RUNX1 t(12;21) cell lines REH and COG-LL-355h as compared to other cell lines (Supplementary Fig. 1c), which was also associated with unphosphorylated peptides (covering the 163 and 165 active residues, Supplementary Fig. 1d for a linear and a 3D structure), suggesting a kinase activity characteristic for the autophagy-related Complex 117. Finally, autophagic flux was investigated using Bafilomycin A1 (BafA1) in a smaller panel of pre-B-ALL cell lines with Western blotting for LC3B-II18,19. LC3B-II levels were higher in t(12;21)-bearing REH and COG-LL-355h cell lines as compared to two other cell lines (apart from RCH-ACV that has exceptionally high basal levels of LC3B-I protein (Fig. 1e. For the original images, see Supplementary Fig. 6a). Together, these data show a predominant upregulation of Vps34 and ATG14 and of the autophagy- and lysosomal degradation- related genes and pathways in leukemic cells with ETV6-RUNX1 t(12;21) translocation.
Leukemic cells with t(12;21) translocation are sensitive to autophagy/lysosomal inhibition
Based on the data above, we asked whether increased levels of Vps34 and ATG14 as well as activity of the autophagy and lysosomal pathways in cells harboring the ETV6-RUNX1 t(12;21), can lead to a dependence on these proteins’ and pathways’ activity for cell survival. An initial automated high throuput drug testing assay using lysosomal inhibitors HCQ and Lys-01, and a Vps34i SAR405 at a wide range of concentrations showed a higher sensitivity of ETV6-RUNX1 cells for HCQ as compared to other pre-B ALL cell lines (Supplementary Table 2 and Supplementary Fig. 2a). Western blotting for LC3B-II verified that the inhibitors indeed inhibited the lysosomal or autophagy pathways: CQ led to the accumulation of LC3B-II, as an inhibitor of autophagosome-lysosome fusion; Vps34i SAR405 inhibited autophagic flux measured in BafA1-treated cells and manifested by a decrease in LC3B-II (Fig. 2a, most prominently in RCH-ACV). ATG14i L309-1229 should selectively block Vps34-complex I activity, and therefore autophagic flux; these effects were, however, less pronounced (Fig. 2a, lower panel).
We next fine-tuned the range of concentrations for each compound and cell line to avoid non-specific toxicities, and performed drug sensitivity assay in 96-well-plate format. We used water soluble dimeric CQ, Lys-0520 and also added a more potent Vps34i, PIK-III7, an ULK1/2 kinase inhibitor, ULK101, acting upstream of Vps34, and the above mentioned ATG14i, L309-12298. The calculated drug sensitivity scores (DSS21) showed that ETV6/RUNX1 t(12;21) cell lines were more sensitive to CQ, HCQ and Lys-05, and to PIK-III and ATG14i than other pre-B-ALL cell lines (Table 1 and Fig. 2b, c). This was not the case, however, for SAR405 or ULK1/2i (Fig. 2b, c).
Table 1.
DRUG/Compound | COG-LL-355h | REH | MHH-CALL-2 | RCH-ACV | SEM | KASUMI-9 |
---|---|---|---|---|---|---|
Chloroquine | 22.5 | 28.3 | 20.6 | 9.5 | 5.3 | 2.1 |
Hydroxychloroquine | 19 | 13.4 | 11.1 | 10.1 | 1.7 | 4 |
LYS-05 | 29.5 | 21.1 | 15 | 15.4 | 6.4 | 5.3 |
PIK-III | 29 | 27.6 | 21 | 22 | 20.7 | 7.6 |
SAR405 | 7 | 8.9 | 10.7 | 14.5 | 11 | 4.3 |
ULK-101 | 1.4 | 4.3 | 2.8 | 0 | 28.1 | 4.4 |
L309-1226 | 21.6 | 16.5 | 9.4 | 7.2 | 11.1 | 4.8 |
Higher DSS values indicate higher sensitivity.
We then assessed apoptotic cell death using caspase 3/7 reagent and IncuCyte live-cell imaging over time (Fig. 2d, e and Supplementary Fig. 2b, c for cell confluence). Lysosomal inhibitors CQ and Lys-05, and Vps34i PIK-III strongly induced cell death in the two ETV6/RUNX1 t(12;21) cell lines but not in the two other cell lines (Fig. 2d, compare upper to lower graphs, note difference in values on Y-axis; Fig. 2e for quantification). Finally, ex vivo treatment of primary patient-derived leukemic cells of different cytogenetic background with lysosomal and Vps34 inhibitors showed that cells from the two ETV6/RUNX1 t(12;21) bearing samples were significantly more sensitive to PIK-III as compared to cells from other pre-B-ALL genetic sub-groups or T-ALL (Fig. 2f and Supplementary Tables 3 and 4 for patient information and DSS scores, respectively). Together these experiments showed that ETV6/RUNX1 t(12;21)—bearing leukemic cells were more sensitive, although with some variation, to the lysosomal or Vps34 inhibition, as compared to cells from other genetic sub-groups. In overall, the Vps34i PIK-III was superior to all other drugs in preferential killing of t(12;21)—bearing leukemic cells.
Inhibitors of autophagy and Dexamethasone synergize in induction of cell death
Apart of being activated in cancer cells, autophagy is also induced by the cytotoxic drugs. Previously, we have shown that Dexamethasone (Dexa), a cornerstone drug used in ALL treatment, induced profound autophagy in ALL cells13,14. As autophagy is often a cytoprotective mechanism in cells, we asked whether combination of Dexa with autophagy inhibition could potentiate cell death of ALL cells.
Both the Western blotting and transcriptome analysis of previously published data15 revealed an absence of glucocorticoid receptor, GCR (NR3C1), in REH cells, low levels in Kasumi-9 cells, with moderate to high levels of expression in other cell lines (Supplementary Fig. 3a, b, respectively). GCR moved to the nucleus upon treatment with Dexa in cell lines with both the high or low levels of expression demonstrating a functional GCR (data not shown). There was also a correlation between GCR (NR3C1) protein expression and sensitivity to Dexa in our previously published data15 (Pearson correlation coefficient = 0.75, Supplementary Fig. 3c). Using this data, we have chosen five pre-B-ALL (Fig. 3) and five T-ALL (Fig. 4) cell lines, based on their moderate levels of GCR expression and intermediate sensitivity to Dexa, and performed combination treatments using Dexa and either lysosomal (HCQ, Lys-05) or autophagy inhibitors (SAR405, PIK-III) (for ZIP scores, see Table 2 and Supplementary Fig. 3d). Combination of Dexa with each of the inhibitors significantly decreased SEM and RCH-ACV cell viability as compared to single treatments (Fig. 3a and c, respectively). High throughput combination treatments for the five pre-B-ALL and five T-ALL cell lines showed universally high synergy between Dexa and lysosomal inhibitors Lys-05 or HCQ in all cell lines (Table 2, Fig. 3b, d and Fig. 4 a, b and Supplementary Fig. 4). Notably, synergy between these drug pairs is achieved even at lower drug concentrations. Synergy between Dexa and the Vps34is SAR405 or PIK-III was weaker as a rule with superior effects of PIK-III over SAR405 (Table 2, Fig. 3b, d and Fig. 4a, b, Supplementary Fig. 3d).
Table 2.
Drug combination | Pre-B-ALL | T-ALL | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
SEM | RCH-ACV | LC4-1 | NALM-6 | 697 | P12-ISCHIKAWA | KARPAS-45 | CCRF-CEM | CCRF-HSB2 | ALL-SIL | |
Lys05-Dexamethasone | 8.96 | 8.45 | 12.4 | 8.99 | 8.05 | 7.51 | 8.75 | 11.86 | 9.53 | 9.34 |
SAR405-Dexamethasone | 2.7 | 4.13 | 8.39 | 8.0 | 2.25 | 1.77 | 0.75 | 4.9 | 1.68 | 0.64 |
HCQ-Dexamethasone | 25.47 | 20.77 | 52.13 | 34.36 | 16.65 | 16.23 | 8.23 | 28.33 | 4.9 | 15.26 |
PIKIII-Dexamethasone | 3.61 | 5.88 | N/A | N/A | N/A | 3.5 | N/A | 1.6 | N/A | N/A |
We then studied apoptosis in pre-B-ALL cell lines SEM and RCH-ACV, and T-ALL cell lines P12-ICHIKAWA and CCRF-CEM treated with all drug combinations over time monitored by Caspase 3/7 activation and live-cell imaging analysis (Figs. 3e and 4c, respectively, and Supplementary Fig. 5 for cell confluence and an image example). Data showed significantly higher number of apoptotic cells in the combination as compared to single treatments in either cell line and for each of the drugs. The data suggests that both lysosomal and autophagy inhibition potentiates apoptotic cell death induced by Dexa in ALL cells.
Finally, we tested translatability of our findings in primary ALL blasts isolated from bone marrow (BM) or peripheral blood (PB) of patients with ALL at diagnosis or relapse (6 pre-B-ALL and 5 T-ALL, see Supplementary Table 3). There were synergistic or additive effects between Dexa and HCQ, Lys-05, SAR405 or PIK-III drug-combinations on a majority of samples without any significant difference within the genetic sub-groups (Table 3 and Fig. 5a, b, c). HCQ, Lys-05 and PIK-III showed the best scores (Fig. 5c).
Table 3.
Drug combination | Pre-B-ALL | T-ALL | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
A5085 | A2808 | A4068 | A4348 | A5272 | A4333 | A3834 | A4253 | A2315 | A2664 | A5126 | |
Lys05-Dexamethasone | 6.5 | 13.44 | 7.6 | 4.28 | 8.54 | 8.45 | 2.31 | 11.21 | 5.68 | 13.63 | 14.05 |
SAR405-Dexamethasone | N/A | N/A | 2.51 | 0.31 | 7.6 | N/A | N/A | N/A | 2.12 | − 1.22 | N/A |
PIKIII-Dexamethasone | N/A | 3.82 | 6.1 | 4.23 | 20.92 | N/A | 0.74 | 12.17 | 12.02 | 9.3 | 6.68 |
HCQ-Dexamethasone | N/A | N/A | 10.33 | 12.3 | 20.98 | N/A | N/A | 5.47 | 10.32 | 14.68 | N/A |
Taken together, our results show that inhibition of lysosomal/autophagy pathways enhanced the cytotoxic effects of GCs in ALL blasts, and inhibitors of these pathways can be used to sensitize to GCs and even overcome GC resistance in ALL (a schematic hypothesis in Fig. 5d).
Discussion
In this pre-clinical study we have shown that inhibition of autophagy by either lysosomal or more selective autophagy inhibitors can be beneficial for the treatment of pediatric acute leukemia. We have studied this using two different approaches: (1) drugs that can be used as precision therapeutics in a particular genetic sub-group of ALL and (2) drug candidates for a combination therapy with GCs.
Pediatric ALL divided into immunological sub-types of pre-B-ALL and T-ALL is a genetically heterogenous disease with more than 10 genetic subgoups9 and, therefore, we asked if any of these subgroups can be selectively dependent on the autophagy or lysosomal pathways. We have analyzed RNAseq and proteomics data from our recent studies on large collection of cell lines15,16 and used existing drugs, such as lysosomal inhibitor HCQ, more potent derivative Lys-0520 or novel selective compounds targeting autophagy4,5,7. We found high levels of Vps34 and autophagy in leukemic cells of ETV6-RUNX1 t(12;21) genetic subgroup and a higher sensitivity of these cells to the lysosomal inhibitors, as compared to other genetic subgroups, being in line with one previous publication that showed a dependence of ETV6-RUNX1 bearing cells on Vps3411. Also, ATG14 protein22 was highly expressed, and one of the Vps34 proteoforms was enriched in cells of this genetic subgroup. We further showed that targeting just Vps34 or ATG14, both required for autophagy initiation, can be beneficial in this particular genetic subgroup. There were variations in the efficiency of the inhibitors. One of the Vps34is, PIK-III, was more effective suggesting that it might be a matter of potency or a more selective activity. While higher levels of Vps34 in ETV6-RUNX1 cell lines require higher drug concentrations for a complete inhibition of Vps34, a more potent Vps34i, such as PIK-III7, has stronger effects. Notably, we could show a superior effect of PIK-III also in t(12;21) primary leukemic cells collected at diagnosis as compared to cells of other genetic sub-groups or T-ALL. With regard to the ATG14i, L309-1226, that blocks protein–protein interaction between Beclin1 and ATG14L8, no inhibition of autophagic flux was observed in RCH-ACV or Sup-B15 cells (as in case of Vps34i SAR405 by measuring LC3B-II formation in the presence of BafA1). ATG14 is initially localized to the phagophore or isolation membrane in a PI3-kinase Complex I together with co-binding proteins2,22. However, in addition, ATG14 oligomers can to be recruited to facilitate autophagosome fusion with lysosomes at the late stages of autophagy23. Thus, L309-1226 can also block autophagy at later stages resulting in accumulation of LC3B-II (rather than inhibiting its formation), which was exactly what we have observed. Taken together, our data suggest that lysosomal and autophagy inhibition could be an efficient way to selectively target ETV6-RUNX1 bearing leukemic cells. Since over-treatment is one of the problems of the current treatment protocols, and ETV6-RUNX1 genetic subgroup is usually associated with a favorable prognosis, the treatments based on biomarkers are warranted, and our work may represent such a precision medicine opportunity in ALL.
Many studies demonstrated that various cytotoxic drugs used in anti-cancer treatment can induce cytoprotective autophagy1,4, leading to clinical trials combining these anti-cancer agents with lysosomal drugs. We previously found that Dexa, uniformly used in the treatment of ALL, induces profound autophagy, which is required for the onset of apoptosis13. The mechanism of this was unknown, but we speculate that it involves signaling pathways (such as production of a pro-apoptotic cleaved form of ATG-5 or down-regulation of BCL2 family members) rather than autophagic cell death. This is supported by the cell death mechanism by caspase-dependent apoptosis24, and by the observation that accelerating autophagy by either mTOR inhibition or amino acid starvation did not result in any further increased cell death13. There are publications on both the pro-survival and pro-death effects of autophagy in leukemias25, and the reasons are not well understood. Therefore, we decided in this study to expand to more cell lines, including T-ALL, and primary ALL cells, and to block autophagy at both the initiation stage with more selective autophagy inhibitors and at the later stage of lysosomal degradation. This approach was also motivated by our recent findings describing upregulation of the lysosomal pathway by Dexa14. Our data clearly showed a strong synergy between Dexa and lysosomal drugs in inducing loss of viability and induction of apoptosis in both pre-B- and T-ALL, independently of their genetic background. A less pronounced but clear either synergistic or significant additive cytotoxic effects of Vps34is were observed. Thus, we can conclude that while some initial signaling leading to autophagy induction might be necessary for cell death, the profound autophagy induced by Dexa primarily has cytoprotective effects. Similar data using CQ were obtained in a most recent study that also showed induction of autophagy and mitophagy in Dexa-treated T-ALL cells26. Another treatment modality in pediatric ALL is L-Asparaginase (Asp), which also induced autophagy, and the combination of Asp and CQ was synergistic in ALL cell lines11. These data together suggest that autophagy inhibition can be beneficial in combination with existing therapeutic modalities in pediatric ALL treatment.
Another important question to discuss is whether elevated autophagy may underlie GC resistance, and whether treatment with lysosomal or selective autophagy inhibitors could alleviate such resistance to GCs in ALL. GCs are especially important since GC-resistance is a prognostic factor in childhood ALL12, representing important point of failure impacting patients during treatment. We and others have found a correlation between levels of GC receptor (GCR or NR3C1) expression and sensitivity to Dexa15. Thus, low levels of GCR may represent a biomarker for combination treatment with lysosomal inhibitors. In this study, we have chosen cell lines with intermediate levels of GCR and intermediate sensitivity to Dexa and showed that it is possible to potentiate Dexa-induced cell death by autophagy inhibition in such cells. On the other hand, several other reasons for GC resistance have being described, such as impaired apoptosis27, metabolic reprograming towards elevated carbohydrate metabolism28 or increased fatty acid oxidation26. In a recent study, increased autophagy/mitophagy was linked to acquired resistance to Dexa, since autophagy was cytoprotective in the resistant to Dexa cells26. We, however, found in the present study that autophagy inhibition can further potentiate cytotoxicity even in cells initially sensitive to GCs, such as in patient-derived primary ALL cells.
The relationship between metabolic reprograming in response to Dexa and autophagy induction remains to be studied. We and others have found that Dexa treatment leads to an inhibition of glucose uptake and metabolism and a switch from glycolysis and glutaminolysis to a fatty acid oxidation26,29. However, while neither low glucose not 2-DG induced or synergized with autophagy induction29, low glutamine levels in media accelerated Dexa-induced autophagy, suggesting that availability of glutamine and also production of ammonia may underlie induction of autophagy by Dexa14. Certainly, recently described Dexa targeting to mitochondria, mitochondria damage and ROS production in response to Dexa is another plausible mechanism26. Future studies using a reliable and fast method to measure autophagy in primary leukemic cells at diagnosis and correlate autophagy to Dexa sensitivity ex vivo can help answering the question of the role of autophagy in GC resistance in leukemic cells.
In conclusion, our present study together with previous research strongly suggests the use of autophagy inhibition for combination therapy to overcome or even to prevent therapy resistance to such important drugs as GCs in ALL. Keeping in mind that high doses of GCs for the treatment of children with ALL has severe side effects that can be devastating and long-lasting9, combining GCs with lysosomal or autophagy inhibitors might make it possible to lower the doses and thus alleviate these side effects.
Significance
In the present study, we used global proteomics and transcriptomics-based approaches and drug testing, to identify autophagy/lysosomal pathways as valid therapeutic targets in a subgroup of pediatric ALL. Further, combining autophagy inhibition with glucocorticoids, cornerstone drugs in the ALL treatment, resulted in synergistic cytotoxic effects in both the cell lines and primary leukemic cells. Thus, our data provide a basis for targeting autophagy/lysosomal pathways in ALL treatment and thus take a step towards personalized treatment of pediatric patients with ALL.
Methods
Cell culture and treatments
Cell culture
Human leukemia-derived cell-lines with indicated chromosomal rearrangements or genetic abberrations used in this study are summarized in Supplementary Table 1 and our recent study15. RPMI 1640 (#R2405, Sigma Aldrich, Solna, Sweden) or Iscove’s Modified Dulbecco’s Medium (Cat.# I2911, Sigma Aldrich) medium were supplemented with 10% or 20% of heat-inactivated fetal bovine serum (FBS) (Cat.# F9665 Gibco), 25 mM HEPES (Cat.# 15630080 Gibco) and 1% penicillin–streptomycin (Cat.# 10378016 Gibco) and 1% L-Glutamine (Cat.# A2916801 Gibco). 1% Insulin–transferrin–sodium selenite (ITS) (Cat.# I3146 Sigma Aldrich) was used for COG-LL-355h. All cell lines were maintained in a humidified incubator with 5% CO2 at 37 °C.
The following compounds were used for drug testing and combination treatments: Dexamethasone (Cat.# D4902 Sigma Aldrich), Chloroquine (Cat.# S4157 Selleckchem), Hydroxychloroquine (Cat.# H0915 Sigma Aldrich), LYS-01 (kindly provided by Dr. Amaravadi), LYS-05 (Cat.# S8369 Selleckchem), SAR405 (Cat.# S7682 Selleckchem), PIK-III (Cat.# S7683 Selleckchem), ULK-101 (Cat.# S8793 Selleckchem), L309-1226 (ChemDiv) and Bafilomycin A1 from Streptomyces griseus (Cat.# B1793 Sigma Aldrich). The compounds were purchased in solid form and reconstituted in 100% dimethyl sulfoxide (DMSO) (Cat.# D8418 Sigma Aldrich), except for Chloroquine and Hydrochlroquine which were dissolved in water. For long-term storage, the compound stocks were aliquoted and kept at − 20 °C.
Publicly available gene expression and thermal proteome profiling data
Bulk RNA-seq based gene expression data of 41 pre-B ALL cell lines published by us15 was retrieved from NCBI’s Gene Expression Omnibus accessible through GEO Series accession number GSE168386. Proteomics-based gene expression data from that study were dowloaded from the ProteomeXchange Consortium via the PRIDE partner repository using the dataset identifier PXD023662. As described in our previous publication, a dataset was assembled including transcriptomic data for a total of 417 leukemia samples from pediatric patients obtained from The European Genome-phenome Archive (EGA) (Dataset ID: EGAD00001002704 and EGAD00001002692) after Data Access Agreement (DAC) approval from St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project Steering Committee, as well as two additional RNA-seq samples of MEF2D-HNRNPUL1 subtype obtained from the Shanghai Institute of Hematology (SIH) processed together with the St. Jude cohort15. Differential gene expression analysis was performed on the RNA-seq data using the R Bioconductor package edgeR30 implemented in a shiny app or using the DESeq2 R package31. Gene enrichment analysis was also performed in R with Over-Representation Analysis (ORA) using log fold changes (logFC) of core:upregulated genes between the ETV6-RUNX1 subtype and other pre-B ALL cells. Data were filtered to include only genes with logFC > 0.3, P value < 0.05, log counts per million (logCPM) > 1, and the false discovery rate was set as fdrThr = 0.05. Comprehensive pathway enrichment analysis was performed using the CRAN-based WebGestalt R package32 using either the Gene Ontology Biological Process (GO:PB)33 or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment databases34.
The relative abundances and melting profiles of Vps34 protein complexes were assessed using Thermal Proteome Profiling (TPP) as described in our recent study16. TPP data for VPS34 was retrieved, also available in raw form on PRIDE with the dataset identifier PXD031162 and browsable at https://www.proteomics.se/deepmeltome/. In brief, peptide mappings were obtained with Leiden-assigned clustering at resolution 1. Domain descriptions, including modification sites, were obtained from Uniprot under the accession Q8NEB9. Peptide mappings and coordinates were assigned for all detected peptides from the FASTA sequence associated with this accession, and the structural visualization plot was downloaded from https://alphafold.ebi.ac.uk/ as generated using the AlphaFold Monomer v2.0 pipeline.
Cell viability and drug combination assay
Cells were seeded at 2 × 105 cells/mL in 96-well flat-bottom white plates (Cat.# 136101, Thermo Fischer) for all cell lines except for COG-LL-355h cell line, which was seeded at 4 × 105 cells/mL. Cells were incubated at 37 °C and 5% CO2 in a humidified incubator for 24 h before treatments. The DMSO levels were normalized across the plate at a maximum of 0.1%. Drugs were serially diluted with concentrations ranging from 0.3 to 10 µM for Vps34 inhibitors and 1.5 to 50 µM for lysosomal inhibitors in a 96-well plate format. Cells were incubated with drugs/compounds for 72–96 h, before measuring cell viability using CellTiter-Glo 2.0 ATP reagent (Promega) on Varioscan LUX microplate reader. Relative cell viabilities were subsequently determined by normalizing to cell-only (100% viability) and medium-only (0% viability) wells and further curve-fitted using a nonlinear regression model (variable slope, four-parameter, GraphPad Prism) when applicable to determine IC50 values. To establish drug sensitivity score (DSS21) values, a standardized Drug Sensitivity and Resistance Testing (DSRT) tool35 was used.
For high throughput assays, compounds were pre-spotted onto 384-well plates (Greiner) using an Echo 550 acoustic dispensing system (Beckman Coulter). When applicable, the DMSO levels were normalized across the plate at a maximum level of 0.1%. Cells were then seeded into the compound-containing plates using a Multidrop Combi Reagent Dispenser (Thermo Fisher Scientific), at 4 × 105 cells/mL in 50 μL medium. Cells were then incubated at 37 °C and 5% CO2 in a humidified incubator for 72 h, before measuring cell viability using CellTiter-Glo on either Varioscan LUX (Thermo Fisher Scientific) microplate reader or EnSight (PerkinElmer) microplate reader.
IncuCyte live-cell imaging
Clear flat-bottom 96-well plates (Cat.# 3599, Corning) were coated with 0.01% Poly-L-ornithine solution (Cat.# P4957, Thermo Fischer Scientific, Stockholm, Sweden) for 24 h at 37 °C, washed with PBS and air dried for 30 min before cells were seeded at 2 × 105 cells/mL (4 × 105 cells/mL for COG-LL-355h) in 100 µL of appropriate complete growth medium. 24 h later both the compounds for treatment and 1 μM of Cellevent Caspase-3/7 Green Dye (Cat.# C10723, Thermo Fischer Scientific) was added to cells. 0.1 µM of staurosporine was used as a positive control for apoptosis induction in every experiment. Phase-contrast and green fluorescence images (10X) were acquired using IncuCyte (Sartorius) every 2 h for 72 h, and cell confluence (%) was calculated using the IncuCyte S3 live-cell analysis system (Sartorius). Caspase 3/7 induction was calculated as per cent of green fluorescent object counts normalized to cell confluence.
Western blot and antibodies
Cell pellets were lysed in freshly prepared modified RIPA buffer (50 mM Tris–HCl pH7.4, 150 nM NaCl, 1 mM EDTA, 1% NP-40, and 1% glycerol) containing protease inhibitor cocktail and phosphoSTOP (Roche). The protein concentration of the extracts was measured using a bicinchoninic acid (BCA) assay (Thermo Fischer Scientific). A total of 30 µg of the proteins were separated on 4–12% or 12% Bis–Tris gels (NuPAGE, Life Technologies), followed by transfer on a methanol-activated polyvinylidene fluoride (PVDF) membrane. Membranes were then cut according to protein sizes (for LC3B, GAPDH, GCR or β-actin), blocked with 5% skimmed milk and incubated with respective primary antibodies diluted in blocking agent overnight at 4 °C, followed by a 1-h incubation with secondary antibodies at room temperature. Proteins were detected using Western Lightening Plus-ECL (PerkinElmer) and visualized using iBright FL1000/ Invitrogen and iBright FL1000 Imaging system software (ThermoFisher Scientific). Ratios of LC3B-II to GAPDH or to β-actin were quantified using Image J and presented under each figure.
The following primary antibodies from Cell signalling Technology were used: anti-LC3B-II (Rabbit, D11, Cat.# 3868S); Anti-GCR (Rabbit mAb D6H2L XP, Cat.# 12041). Anti-β-Actin (Rabbit, Cat.# 4967). Anti-GAPDH was from Santa Cruz Biotechnology (Mouse, 0411, Cat.# sc-47724). Secondary antibodies were: Goat anti-rabbit IgG HRP-linked, Cell Signalling Technology Cat.# 7074, Goat anti-mouse Ig (H + L) HRP, Fischer Scientific, Cat# 626520.
Primary ALL samples and cell culture
Isolation of mononuclear cells
Leukemic cells were obtained from bone marrow or peripheral blood from patients with primary ALL at diagnosis or relapse. Mononuclear cells were obtained by density gradient centrifugation using SepMate™ tubes (Cat.# 15450 STEMCELL Technologies), according to the manufacturer’s instructions. Isolated leukemic cells were cryopreserved in liquid nitrogen in FBS/10% DMSO.
Patient samples
The study included leukemic cells from patients diagnosed with precursor-B-ALL or T-ALL according to the World Health Organization classification36, for details see Supplementary Table 3. All patients and their parents were informed of the investigative nature of this study, and informed consent was obtained from each patient/parent in accordance with the ethical committee requirements; the experimental protocols for isolation of mononuclear cells from blood and bone marrow, for their long-term storage and usage in the methods described were approved by the following decisions: 01-069, amendment 2021-02718; 02-445 amendment 2018/38-32, Swedish Ethical Review Authority (Etikprövningsmyndigheten), Stockholm, Sweden. All experiments were performed according to Karolinska institutet’s guidelines and regulations; risk assessment for work with blood and other human materials were made in HUMRA according to institutets rules, and the experimental protocol was approved by the group leader.
Culturing protocol, drug treatment and cell viability
For the treatments, primary cells were washed, counted and seeded in Iscove’s modified MDM (Sigma Aldrich, I2911) containing 20% FBS, 1% of ITS Liquid Media Supplement (Sigma Aldrich) 1% L-Glutamin and 1% of penicillin–streptomycin in either 96-well plates or in 384-well plates, as described for cell lines, and 3 h later were treated with drugs for 48 h. Cell viability was assessed using CellTiter-Glo 2.0 (Promega).
Data analysis
Graphs and statistical analyses were performed using GraphPad (Prism). Comparisons between groups were performed using two-tailed unpaired t-tests or one-way analysis of variance to compare three or more groups. P values of < 0.05 (*), < 0.01 (**), < 0.001 (***), < 0.0001 (****) were determined to be statistically significant. Sample size (n) refers to biological replicates. Synergy between two drug pairs was determined using the SynergyFinder package version 2.4 in R21 and values for Zero interaction potency (ZIP) were used. Based on ZIP synergy scoring model, a delta (Δ%) score below zero antagonistic, between 0 and 5 is additive and above 5 is synergistic.
Data availablity
The datasets generated during the current study are available from the corresponding author on request. Data originating from outside of this study are appropriately referenced and publicly available from that source.
Supplementary Information
Acknowledgements
This study was supported with grants from Swedish Cancer Society and Cancer Society of Stockholm, 1910. The authors thank Ishani Das, PhD, for valuable guidance during initial work on establishing experimental systems for drug testing.
Author contributions
H.C.B., I.R.L. and K.P.T. designed the study. H.C.B., I.R.L., N.S, A.T., A.K., I.D., B.S.L. performed the experimets. N.S., T.E., H.C.B. and B.S.L. designed and performed high throuput automated experiments. M.H. and G.R. provided patient medical/pathology information. K.P.T. and R.J. provided cell line and patient material. R.J., I.R.L. and L.A. provided proteomics, mRNAseq and proteoform data and performed data analysis. H.C.B. performed statistical analysis and prepared the figures. H.C.B. and K.P.T. wrote the manuscript and all authors participated in the manuscript preparation and revision.
Funding
Open access funding provided by Karolinska Institute.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-024-54400-6.
References
- 1.Onorati AV, Dyczynski M, Ojha R, Amaravadi RK. Targeting autophagy in cancer. Cancer. 2018;124:3307–3318. doi: 10.1002/cncr.31335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kihara A, Noda T, Ishihara N, Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J. Cell Biol. 2001;152:519–530. doi: 10.1083/jcb.152.3.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ohashi Y, Tremel S, Williams RL. VPS34 complexes from a structural perspective. J. Lipid Res. 2019;60:229–241. doi: 10.1194/jlr.R089490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Dyczynski M, et al. Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. Cancer Lett. 2018;435:32–43. doi: 10.1016/j.canlet.2018.07.028. [DOI] [PubMed] [Google Scholar]
- 5.Nagelkerke A, Bussink J, Geurts-Moespot A, Sweep FC, Span PN. Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy. Semin. Cancer Biol. 2014 doi: 10.1016/j.semcancer.2014.06.001. [DOI] [PubMed] [Google Scholar]
- 6.Ronan B, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat. Chem. Biol. 2014;10:1013–1019. doi: 10.1038/nchembio.1681. [DOI] [PubMed] [Google Scholar]
- 7.Dowdle WE, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat. Cell Biol. 2014;16:1069–1079. doi: 10.1038/ncb3053. [DOI] [PubMed] [Google Scholar]
- 8.Pavlinov I, Salkovski M, Aldrich LN. Beclin 1-ATG14L protein-protein interaction inhibitor selectively inhibits autophagy through disruption of VPS34 complex I. J. Am. Chem. Soc. 2020;142:8174–8182. doi: 10.1021/jacs.9b12705. [DOI] [PubMed] [Google Scholar]
- 9.Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–1955. doi: 10.1016/S0140-6736(12)62187-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Downing JR, et al. The pediatric cancer genome project. Nat. Genet. 2012;44:619–622. doi: 10.1038/ng.2287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Polak R, et al. Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Haematologica. 2019;104:738–748. doi: 10.3324/haematol.2018.193631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Schrappe M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205–2222. doi: 10.1038/sj.leu.2401973. [DOI] [PubMed] [Google Scholar]
- 13.Laane E, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ. 2009;16:1018–1029. doi: 10.1038/cdd.2009.46. [DOI] [PubMed] [Google Scholar]
- 14.Dyczynski M, et al. Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment. Cell Death Dis. 2018;9:846. doi: 10.1038/s41419-018-0625-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Leo IR, et al. Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. Nat. Commun. 2022;13:1691. doi: 10.1038/s41467-022-29224-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kurzawa N, et al. Deep thermal profiling for detection of functional proteoform groups. Nat. Chem. Biol. 2023 doi: 10.1038/s41589-023-01284-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kim J, Guan KL. AMPK connects energy stress to PIK3C3/VPS34 regulation. Autophagy. 2013;9:1110–1111. doi: 10.4161/auto.24877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016;12:1–222. doi: 10.1080/15548627.2015.1100356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140:313–326. doi: 10.1016/j.cell.2010.01.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.McAfee Q, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc. Natl. Acad. Sci. U. S. A. 2012;109:8253–8258. doi: 10.1073/pnas.1118193109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 2015;13:504–513. doi: 10.1016/j.csbj.2015.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol. Biol. Cell. 2008;19:5360–5372. doi: 10.1091/mbc.e08-01-0080. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Diao J, et al. ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. Nature. 2015;520:563–566. doi: 10.1038/nature14147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Laane E, et al. Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica. 2007;92:1460–1469. doi: 10.3324/haematol.10543. [DOI] [PubMed] [Google Scholar]
- 25.Evangelisti C, et al. Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. Biochim. Biophys. Acta. 1853;1853:14–26. doi: 10.1016/j.bbamcr.2014.09.023. [DOI] [PubMed] [Google Scholar]
- 26.Olivas-Aguirre M, et al. Dexamethasone-induced fatty acid oxidation and autophagy/mitophagy are essential for T-ALL glucocorticoid resistance. Cancers. 2023 doi: 10.3390/cancers15020445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Holleman A, den Boer ML, Kazemier KM, Janka-Schaub GE, Pieters R. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood. 2003;102:4541–4546. doi: 10.1182/blood-2002-11-3612. [DOI] [PubMed] [Google Scholar]
- 28.Holleman A, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 2004;351:533–542. doi: 10.1056/NEJMoa033513. [DOI] [PubMed] [Google Scholar]
- 29.Buentke E, Nordström A, Lin H, Björklund AC, Laane E, Harada M, Lu L, Tegnebratt T, Stone-Elander S, Heyman M, Söderhäll S, Porwit A, Östenson CG, Shoshan M, Pokrovskaja Tamm K, Grandér D. Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. Blood Cancer J. 2011;1:e31. doi: 10.1038/bcj.2011.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140. doi: 10.1093/bioinformatics/btp616. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res. 2017;45:W130–W137. doi: 10.1093/nar/gkx356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Ashburner M, et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25–29. doi: 10.1038/75556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Ogata H, Goto S, Fujibuchi W, Kanehisa M. Computation with the KEGG pathway database. Biosystems. 1998;47:119–128. doi: 10.1016/s0303-2647(98)00017-3. [DOI] [PubMed] [Google Scholar]
- 35.Potdar S, et al. Breeze: An integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics. 2020;36:3602–3604. doi: 10.1093/bioinformatics/btaa138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Swerdlow, S. H., Campo, E. Lee Harris, N., Jaffe, E. S., Pileri, S. A., Stein, H., Thiele, J. & Vardiman, J. W. WHO Classification of Tumours of Haematopoietic and Lymphatic Tissues (The International Agency for Research on Cancer, IARC, 2008).
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.